首页> 外文期刊>Clinical Psychopharmacology and Neuroscience >Association Study of Fat-mass and Obesity-associated Gene and Body Mass Index in Japanese Patients with Schizophrenia and Healthy Subjects
【24h】

Association Study of Fat-mass and Obesity-associated Gene and Body Mass Index in Japanese Patients with Schizophrenia and Healthy Subjects

机译:日本精神分裂症患者和健康受试者脂肪与肥胖相关基因与体重指数的关联研究

获取原文
       

摘要

Objective Fat-mass and obesity-associated (FTO) gene is known to be involved in the pathophysiology of obesity and a single-nucleotide polymorphism (SNP) rs9939609 of FTO gene is repeatedly confirmed to be associated with body mass index (BMI) and obesity. The aim of this study is to elucidate effects of FTO gene polymorphism on BMI in Japanese patients with schizophrenia and healthy subjects. Methods Three hundred fifty one patients with schizophrenia and 342 age- and sex-matched healthy subjects participated in the study. Information on BMI and antipsychotic medication was also collected from patients and healthy subjects. Genotype of the FTO SNP rs9939609 was determined by TaqMan SNP Genotyping Assays. Results There was no significant difference in BMI between patients and healthy subjects. No significant difference in BMI was observed among any medications. We observed no significant difference in rs9939609 allele frequencies between patients and healthy subjects. There was a significant difference in BMI between healthy subjects with risk (AA or TA) genotypes and those with TT genotype. We also observed a significant positive correlation between the number of risk allele (A allele) and BMI in healthy subjects. Conclusion Our study suggested that FTO rs9939609 polymorphism might have some impacts on the BMI in healthy subjects, but might not have same impacts on the BMI of patients with schizophrenia.
机译:已知与肥胖和肥胖相关的目标基因(FTO)与肥胖的病理生理有关,并且反复确认该FTO基因的单核苷酸多态性(SNP)rs9939609与体重指数(BMI)和肥胖相关。这项研究的目的是阐明日本精神分裂症患者和健康受试者的FTO基因多态性对BMI的影响。方法351例精神分裂症患者和342名年龄和性别相匹配的健康受试者参加了研究。还从患者和健康受试者中收集了有关BMI和抗精神病药物的信息。通过TaqMan SNP基因分型分析确定FTO SNP rs9939609的基因型。结果患者与健康受试者之间的BMI没有显着差异。在任何药物中,未观察到BMI的显着差异。我们观察到患者和健康受试者之间的rs9939609等位基因频率没有显着差异。具有风险(AA或TA)基因型的健康受试者与具有TT基因型的健康受试者之间的BMI存在显着差异。我们还观察到健康受试者中风险等位基因(A等位基因)数量与BMI之间存在显着正相关。结论我们的研究表明FTO rs9939609多态性可能对健康受试者的BMI有一定影响,但对精神分裂症患者的BMI可能没有相同的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号